MarsBio
ActiveVenture Capital
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at MarsBio.
Key people at MarsBio.
Key people at MarsBio.
MarsBio is an early-stage venture firm focused exclusively on transformative bioscience startups. Its mission is to back the boldest entrepreneurs in biology at the very earliest stages—often pre-seed or at the idea stage—enabling scientists and engineers to turn radical scientific insights into impactful companies. The firm’s investment philosophy centers on conviction in founder-led innovation, particularly in deep tech and frontier biology, where long-term vision and technical depth matter more than short-term metrics.
MarsBio invests across a broad spectrum of bioscience domains, including synthetic biology, therapeutics, agricultural biotech, biomaterials, and consumer-facing biotech products. By stepping in when few others will, MarsBio plays a critical role in the startup ecosystem, de-risking the leap from lab to company and helping founders build the infrastructure, teams, and narratives needed to attract follow-on capital. It functions less like a traditional VC and more like a co-founder for science-driven entrepreneurs.
---
MarsBio was founded by a group of entrepreneurs who had themselves launched and scaled science-heavy startups, giving them firsthand experience with the unique challenges faced by technical founders in biotech and deep science. The founding team includes Arye Shapiro, an entrepreneur and life sciences operator who was part of the founding team at ImaginAb, a UCLA spinout in immuno-oncology; Llewellyn Cox, founder of LabLaunch, a leading biotech incubator network in Southern California; and Rob Rhinehart, founder of Soylent and a Y Combinator alum known for building consumer-facing science-based products.
The idea for MarsBio emerged from their shared frustration: too many groundbreaking scientific ideas never made it out of the lab due to lack of early support, mentorship, and patient capital. They created MarsBio explicitly to be “by entrepreneurs, for entrepreneurs,” with the goal of giving scientists and engineers the runway, network, and operational backing they need to build durable, high-impact businesses. The firm’s early traction came from backing a small but highly technical portfolio of companies that quickly advanced into clinical development, raised significant follow-on rounds, or achieved product-market fit in niche but high-value markets.
---
---
MarsBio is riding the long-term shift toward the “Golden Age of Biology”—a period where advances in genomics, synthetic biology, AI-driven drug discovery, and lab automation are collapsing the cost and time required to build biotech companies. The timing is critical: tools like CRISPR, cell-free systems, and cloud labs have democratized access to biology, enabling small teams to do what once required large institutions.
At the same time, traditional biotech investors remain risk-averse at the earliest stages, creating a funding gap that MarsBio is uniquely positioned to fill. By backing founders before they have data, the firm helps accelerate the translation of academic and open-science breakthroughs into real-world products. In doing so, MarsBio is shaping a new model for how deep science gets commercialized—one that blends the speed and agility of tech startups with the rigor of life sciences.
Its influence extends beyond its portfolio: by proving that high-risk, high-reward bets on early science can pay off, MarsBio is helping redefine what’s considered “investable” in biotech and inspiring a new generation of scientist-entrepreneurs to start companies rather than stay in academia.
---
MarsBio is poised to become a defining vehicle for the next generation of biology-driven startups. As the cost of experimentation continues to fall and AI augments biological design, the number of founders who can launch meaningful companies from a laptop (or a shared lab bench) will only grow—and MarsBio is positioning itself as the go-to partner for that cohort.
Looking ahead, the firm is likely to deepen its focus on platform technologies—modular tools in synthetic biology, diagnostics, and biomaterials—that can spawn multiple companies or be licensed widely. It may also expand its operating model, potentially building shared R&D infrastructure or even a bio-focused accelerator in partnership with its incubator network.
The broader trend is clear: biology is becoming programmable, and the winners will be those who back the right founders at the right time. MarsBio’s bet is that the boldest ideas in bioscience don’t start with a term sheet—they start with a question, a hypothesis, and a founder willing to go all-in. By standing behind those moments, MarsBio isn’t just funding companies; it’s helping write the next chapter of the biological revolution.
